Literature DB >> 3049816

Human monoclonal antibodies reactive with antigens of the group A Streptococcus and human heart.

M W Cunningham1, J M McCormack, L R Talaber, J B Harley, E M Ayoub, R S Muneer, L T Chun, D V Reddy.   

Abstract

Human mAb were produced from tonsillar or PBL of normal individuals or patients infected with group A streptococci. Lymphocytes were purified on Ficoll-Hypaque gradients and stimulated in vitro with purified group A streptococcal membranes or M protein extracts. The mAb were selected for study based on their reaction with group A streptococci, pep M5 protein, and/or M6 Escherichia coli protein. Further analysis by Western immunoblot or competitive inhibition ELISA revealed that there were two types of antibodies: one type that reacted with myosin and DNA and the other type that reacted with myosin, keratin, and/or actin. The specificities of these human mAb are similar to specificities observed in our previous studies of murine mAb reactive with group A streptococci and heart Ag. For comparison, anti-myosin antibodies were affinity purified from the sera of infected or acute rheumatic fever patients and were shown to react with myosin and DNA as well as with group A streptococci and M protein. To affinity purify these antibodies from normal sera, five times the amount of sera was required to obtain detectable quantities. These data suggest that the human mAb reactive with group A streptococci and myosin reflect the antibodies seen in sera from infected patients or acute rheumatics and that the B lymphocyte clones capable of producing these cross-reactive antibodies are also present in normal individuals.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3049816

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  Cardiac myosin and the TH1/TH2 paradigm in autoimmune myocarditis.

Authors:  M W Cunningham
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Immunogenic and Genetic Factors in Rheumatic Fever.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

3.  Vaccination against rheumatic heart disease: a review of current research strategies and challenges.

Authors:  Manisha Pandey; Michael R Batzloff; Michael F Good
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

4.  Immunology: Chronic effects of acute infections.

Authors:  Nicola Harris
Journal:  Nature       Date:  2015-10-22       Impact factor: 49.962

5.  Identification of a putative shared epitope between Coxsackie virus B4 and alpha cardiac myosin heavy chain.

Authors:  K W Beisel; J Srinivasappa; B S Prabhakar
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

6.  Immunological relationship between the class I epitope of streptococcal M protein and myosin.

Authors:  A Quinn; K Ward; V A Fischetti; M Hemric; M W Cunningham
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 7.  The role of infections in autoimmune disease.

Authors:  A M Ercolini; S D Miller
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

Review 8.  Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive Antigens of Group A Streptococci and their Sequelae.

Authors:  Madeleine W Cunningham
Journal:  Microbiol Spectr       Date:  2019-07

9.  Cloning and sequence analysis of a gene encoding a 67-kilodalton myosin-cross-reactive antigen of Streptococcus pyogenes reveals its similarity with class II major histocompatibility antigens.

Authors:  K S Kil; M W Cunningham; L A Barnett
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

10.  Repeat exposure to group A streptococcal M protein exacerbates cardiac damage in a rat model of rheumatic heart disease.

Authors:  Davina Gorton; Suchandan Sikder; Natasha L Williams; Lisa Chilton; Catherine M Rush; Brenda L Govan; Madeleine W Cunningham; Natkunam Ketheesan
Journal:  Autoimmunity       Date:  2016-08-25       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.